{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:08:42Z","timestamp":1722888522972},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In patients with mild cognitive impairment (MCI), enhanced cerebral amyloid-\u03b2 plaque burden is a high-risk factor to develop dementia with Alzheimer\u2019s disease (AD). Not all patients have immediate access to the assessment of amyloid status (A-status) via gold standard methods. It may therefore be of interest to find suitable biomarkers to preselect patients benefitting most from additional workup of the A-status. In this study, we propose a machine learning\u2013based gatekeeping system for the prediction of A-status on the grounds of pre-existing information on APOE-genotype <jats:sup>18<\/jats:sup>F-FDG PET, age, and sex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three hundred and forty-two MCI patients were used to train different machine learning classifiers to predict A-status majority classes among APOE-\u03b54 non-carriers (APOE4-nc; majority class: amyloid negative (A\u03b2-)) and carriers (APOE4-c; majority class: amyloid positive (A\u03b2\u2009+)) from <jats:sup>18<\/jats:sup>F-FDG-PET, age, and sex. Classifiers were tested on two different datasets. Finally, frequencies of progression to dementia were compared between gold standard and predicted A-status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A\u03b2- in APOE4-nc and A\u03b2\u2009+\u2009in APOE4-c were predicted with a precision of 87% and a recall of 79% and 51%, respectively. Predicted A-status and gold standard A-status were at least equally indicative of risk of progression to dementia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We developed an algorithm allowing approximation of A-status in MCI with good reliability using APOE-genotype, <jats:sup>18<\/jats:sup>F-FDG PET, age, and sex information. The algorithm could enable better estimation of individual risk for developing AD based on existing biomarker information, and support efficient selection of patients who would benefit most from further etiological clarification. Further potential utility in clinical routine and clinical trials is discussed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-022-05879-6","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T01:02:31Z","timestamp":1657760551000},"page":"4478-4489","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment"],"prefix":"10.1007","volume":"49","author":[{"given":"E.","family":"Doering","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. N.","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. P.","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Ellingsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"5879_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack","year":"2011","unstructured":"Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:257\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR3","doi-asserted-by":"crossref","unstructured":"Haeberlein SB, Hehn C von, Tian Y, et al (2019) EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer\u2019s disease. San Diego, CA","DOI":"10.1002\/alz.047259"},{"key":"5879_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161.","journal-title":"JAMA Neurol"},{"key":"5879_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008866","author":"C Benedict","year":"2020","unstructured":"Benedict C, Blennow K, Zetterberg H, Cedernaes J. Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000008866.","journal-title":"Neurology"},{"key":"5879_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002923","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016. https:\/\/doi.org\/10.1212\/WNL.0000000000002923.","journal-title":"Neurology"},{"key":"5879_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19:951\u201362.","journal-title":"Lancet Neurol"},{"key":"5879_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2967\/jnumed.107.045385","volume":"49","author":"L Mosconi","year":"2008","unstructured":"Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias. J Nucl Med. 2008;49:390\u20138.","journal-title":"J Nucl Med"},{"key":"5879_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3233\/JAD-171125","volume":"64","author":"N Smailagic","year":"2018","unstructured":"Smailagic N, Lafortune L, Kelly S, Hyde C, Brayne C. 18F-FDG PET for prediction of conversion to Alzheimer\u2019s disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy. J Alzheimer\u2019s Dis. 2018;64:1175\u201394.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"5879_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X16654492","author":"F Carbonell","year":"2016","unstructured":"Carbonell F, Zijdenbos AP, Mclaren DG, Iturria-Medina Y, Bedell BJ. Modulation of glucose metabolism and metabolic connectivity by \u03b2-amyloid. J Cereb Blood Flow Metab. 2016. https:\/\/doi.org\/10.1177\/0271678X16654492.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5879_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.pscychresns.2012.04.007","volume":"212","author":"J Dukart","year":"2013","unstructured":"Dukart J, Mueller K, Barthel H, Villringer A, Sabri O, Schroeter ML. Meta-analysis based SVM classification enables accurate detection of Alzheimer\u2019s disease across different clinical centers using FDG-PET and MRI. Psychiatry Res - Neuroimaging. 2013;212:230\u20136.","journal-title":"Psychiatry Res - Neuroimaging"},{"key":"5879_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3174\/ajnr.A1357","volume":"30","author":"Y Yuan","year":"2009","unstructured":"Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to alzheimer disease in patients with mild cognitive impairment: a meta-analysis. Am J Neuroradiol. 2009;30:404\u201310.","journal-title":"Am J Neuroradiol"},{"key":"5879_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a2e8d0","author":"A Drzezga","year":"2009","unstructured":"Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a2e8d0.","journal-title":"Neurology"},{"key":"5879_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4668","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA - J Am Med Assoc. 2015. https:\/\/doi.org\/10.1001\/jama.2015.4668.","journal-title":"JAMA - J Am Med Assoc"},{"key":"5879_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305858","author":"M Lehmann","year":"2014","unstructured":"Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O\u2019Neil JP, Huang Y, Miller BL, Jagust WJ, Rabinovici GD. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. J Neurol Neurosurg Psychiatry. 2014. https:\/\/doi.org\/10.1136\/jnnp-2013-305858.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5879_CR16","unstructured":"Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 2005;46."},{"issue":"10","key":"5879_CR17","first-page":"1","volume":"101","author":"YH Jung","year":"2020","unstructured":"Jung YH, Lee H, Kim HJ, Na DL, Han HJ, Jang H. Seo SW (2020) Prediction of amyloid \u03b2 PET positivity using machine learning in patients with suspected cerebral amyloid angiopathy markers. Sci Reports. 2020;101(10):1\u201310.","journal-title":"Sci Reports"},{"key":"5879_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"JP Kim","year":"2021","unstructured":"Kim JP, Kim J, Jang H, et al. Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Sci Rep. 2021;11:1\u20139.","journal-title":"Sci Rep"},{"key":"5879_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00309","author":"JH Lee","year":"2018","unstructured":"Lee JH, Byun MS, Yi D, Sohn BK, Jeon SY, Lee Y, Lee JY, Kim YK, Lee YS, Lee DY. Prediction of cerebral amyloid with common information obtained from memory clinic practice. Front Aging Neurosci. 2018. https:\/\/doi.org\/10.3389\/fnagi.2018.00309.","journal-title":"Front Aging Neurosci"},{"key":"5879_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/JAD-180048","volume":"66","author":"SE Kim","year":"2018","unstructured":"Kim SE, Woo S, Kim SW, et al. A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment. J Alzheimer\u2019s Dis. 2018;66:681\u201391.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"5879_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-021-00798-3","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim S, Lee P, Oh KT, et al. Deep learning-based amyloid PET positivity classification model in the Alzheimer\u2019s disease continuum by using 2-[18F]FDG PET. EJNMMI Res. 2021;11:1\u201314.","journal-title":"EJNMMI Res"},{"key":"5879_CR22","first-page":"82","volume":"10","author":"T Grimmer","year":"2013","unstructured":"Grimmer T, Wutz C, Drzezga A, Forster S, Forstl H, Ortner M, Perneczky R, Kurz A. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res. 2013;10:82\u20135.","journal-title":"Curr Alzheimer Res"},{"key":"5879_CR23","doi-asserted-by":"crossref","unstructured":"Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. In: J. Intern. Med. J Intern Med, 2004, pp 240\u2013246","DOI":"10.1111\/j.1365-2796.2004.01380.x"},{"key":"5879_CR24","unstructured":"Landau S, Koeppe R, Jagust W (2011) Florbetaben processing and positivity threshold derivation Motivation for changing the threshold."},{"key":"5879_CR25","unstructured":"Landau S, Jagust W. Florbetapir processing methods. 2011."},{"key":"5879_CR26","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193\u20139.","journal-title":"Neurology"},{"key":"5879_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.03.003","author":"WJ Jagust","year":"2010","unstructured":"Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA. The Alzheimer\u2019s Disease Neuroimaging Initiative positron emission tomography core. Alzheimer\u2019s Dement. 2010. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.003.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR28","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1038\/s41598-018-23676-w","volume":"8","author":"BS Ye","year":"2018","unstructured":"Ye BS, Kim HJ, Kim YJ, et al. Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study. Sci Rep. 2018;8:5557.","journal-title":"Sci Rep"},{"key":"5879_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jalz.2010.03.013","volume":"6","author":"AJ Saykin","year":"2010","unstructured":"Saykin AJ, Shen L, Foroud TM, et al. Alzheimer\u2019s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimer\u2019s Dement. 2010;6:265\u201373.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-021-00771-0","volume":"11","author":"A Verger","year":"2021","unstructured":"Verger A, Doyen M, Campion JY, Guedj E. The pons as reference region for intensity normalization in semi-quantitative analysis of brain 18FDG PET: application to metabolic changes related to ageing in conventional and digital control databases. EJNMMI Res. 2021;11:1\u20137.","journal-title":"EJNMMI Res"},{"key":"5879_CR31","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2001.0978","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002. https:\/\/doi.org\/10.1006\/nimg.2001.0978.","journal-title":"Neuroimage"},{"key":"5879_CR32","unstructured":"Molnar C. Permutation feature importance. Interpret. Mach. Learn. - A Guid. Mak. Blackbox Model. Explain. 2021."},{"key":"5879_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of ALZHEIMER\u2019s disease: report of the NINCDS-ADRDA work group\u22c6 under the auspices of Department Of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"key":"5879_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003126","author":"R Wolz","year":"2016","unstructured":"Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DLG. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology. 2016. https:\/\/doi.org\/10.1212\/WNL.0000000000003126.","journal-title":"Neurology"},{"key":"5879_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1194-1","author":"A Drzezga","year":"2003","unstructured":"Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer\u2019s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003. https:\/\/doi.org\/10.1007\/s00259-003-1194-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5879_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520380046012","author":"DA Loewenstein","year":"1989","unstructured":"Loewenstein DA, Barker WW, Chang JY, Apicella A, Yoshii F, Kothari P, Levin B, Duara R. Predominant left hemisphere metabolic dysfunction in dementia. Arch Neurol. 1989. https:\/\/doi.org\/10.1001\/archneur.1989.00520380046012.","journal-title":"Arch Neurol"},{"key":"5879_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.nicl.2018.07.016","volume":"20","author":"CM Weise","year":"2018","unstructured":"Weise CM, Chen K, Chen Y, Kuang X, Savage CR, Reiman EM. Left lateralized cerebral glucose metabolism declines in amyloid-\u03b2 positive persons with mild cognitive impairment. NeuroImage Clin. 2018;20:286\u201396.","journal-title":"NeuroImage Clin"},{"key":"5879_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2021.06.014","volume":"106","author":"J Pfeil","year":"2021","unstructured":"Pfeil J, Hoenig MC, Doering E, van Eimeren T, Drzezga A, Bischof GN. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer\u2019s disease. Neurobiol Aging. 2021;106:119\u201329.","journal-title":"Neurobiol Aging"},{"key":"5879_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068860","author":"G Sanabria-Diaz","year":"2013","unstructured":"Sanabria-Diaz G, Mart\u00ednez-Montes E, Melie-Garcia L. Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer\u2019s disease and mild cognitive impairment. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0068860.","journal-title":"PLoS ONE"},{"key":"5879_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2017.12.037","author":"KL Arnemann","year":"2018","unstructured":"Arnemann KL, St\u00f6ber F, Narayan S, Rabinovici GD, Jagust WJ. Metabolic brain networks in aging and preclinical Alzheimer\u2019s disease. NeuroImage Clin. 2018. https:\/\/doi.org\/10.1016\/j.nicl.2017.12.037.","journal-title":"NeuroImage Clin"},{"key":"5879_CR42","doi-asserted-by":"crossref","unstructured":"Hammes J, Bischof GN, Bohn KP, et al. One stop shop: flortaucipir PET differentiates amyloid positive and negative forms of neurodegenerative diseases. J Nucl Med. 2020.","DOI":"10.1055\/s-0039-1683495"},{"key":"5879_CR43","doi-asserted-by":"publisher","unstructured":"Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.04.007","DOI":"10.1016\/j.neurobiolaging.2010.04.007"},{"key":"5879_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101800","author":"R Duara","year":"2019","unstructured":"Duara R, Loewenstein DA, Lizarraga G, et al. Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity. NeuroImage Clin. 2019. https:\/\/doi.org\/10.1016\/j.nicl.2019.101800.","journal-title":"NeuroImage Clin"},{"key":"5879_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12640","author":"MT Ashford","year":"2022","unstructured":"Ashford MT, Raman R, Miller G, et al. Screening and enrollment of underrepresented ethnocultural. Alzheimer\u2019s Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12640.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.009","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Groot C, Jansen WJ, et al. Prevalence of the apolipoprotein E \u03b54 allele in amyloid \u03b2 positive subjects across the spectrum of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.009.","journal-title":"Alzheimer\u2019s Dement"},{"key":"5879_CR47","unstructured":"Yoke\u015f MB, Emre M, Harmanci H, G\u00fcrvit H, Hana\u01e7asi H, \u015eahin H, Bilgi\u00e7 B, Ba\u015fak AN. The apolipoprotein E (APOE) genotype in a Turkish population with Alzheimer\u2019s disease. Balk. J Med Genet. 2005;8."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05879-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:08:55Z","timestamp":1666757335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05879-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5879"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05879-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and ICH\/GCP guidelines. Approval was granted by the Ethics Committee of the Technical University of Munich (EUDRACT 2006\u2013000762-36). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"TvE reported receiving consulting and lecture fees from Lundbeck A\/S, Lilly Germany, and Shire Germany and research funding from the German Research Foundation (DFG), the Leibniz Association, and the EU-joint program for neurodegenerative disease research (JPND). AD reported receiving research support and speaker honoraria by Life Molecular Imaging, AVID\/Lilly Radiopharmaceuticals, Siemens Healthineers, and GE Healthcare. No other disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}